Insights

Washington – June 8, 2023: Crowell & Moring has been recommended in seven practice areas in the 16th edition of the Legal 500 United States. In addition, partner Daniel R. Forman, co-chair of the firm’s Government Contracts Group, has been named to the Legal 500’s “Hall of Fame” for Government Contracts. The firm’s full rankings can be viewed here.

Denver – January 12, 2023: 5280 Magazine has named Meshach Y. Rhoades, managing partner of Crowell & Moring’s Denver office, to its 2023 list of Denver’s Top Lawyers in the Commercial Litigation category. The ninth annual list features the best attorneys in the region, based on recommendations from peers and follow-up reporting.

On April 12, 2024, the Tenth Circuit issued a decision in I DIG Texas LLC v. Kerry Creager, which analyzed country-of-origin claims in a manner that diverged from the well-established Federal Trade Commission’s “Made in USA” policy.

In late December, the FDA released a guidance document that provides clarity for small businesses marketing direct-to-consumer (DTC) drug products on television or radio.  The Q&A followed the FDA’s November 2023 Final Rule amending DTC advertising regulations for prescription drugs. 

On April 13, 2023, the Federal Trade Commission (“FTC”) announced that it has notified approximately 670 companies of potential FTC advertising regulation violations, triggering FTC authority to pursue steep civil penalties if companies fail to substantiate their product claims.  The target of this crusade is companies primarily advertising over-the-counter drugs, homeopathic products, dietary supplements, and functional foods.  Once on notice, companies could be subject to civil penalties of up to $50,120 per violation for unsubstantiated product claims.

Lorraine Campos,  Toni Michelle Jackson, Trina Fairley Barlow, and Meschach Rhoades will be speaking at the Corporate Counsel Women of Color's 19th Annual Career Strategies Conference.